Vanguard Group Inc. Sells 47,158 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Vanguard Group Inc. lessened its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 0.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,907,815 shares of the company’s stock after selling 47,158 shares during the period. Vanguard Group Inc. owned about 0.06% of Amneal Pharmaceuticals worth $225,638,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of AMRX. Comerica Bank grew its position in shares of Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares during the period. Spire Wealth Management grew its position in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after acquiring an additional 1,023 shares during the period. Focus Partners Wealth bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $42,000. Advisory Services Network LLC bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $50,000. Finally, Bellevue Group AG bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $79,000. Institutional investors own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. UBS Group assumed coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 target price for the company. Truist Financial lifted their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $13.20 on Friday. The company has a market capitalization of $4.15 billion, a price-to-earnings ratio of 34.74 and a beta of 1.32. The company has a 50-day simple moving average of $12.82 and a 200 day simple moving average of $12.73. Amneal Pharmaceuticals, Inc. has a 52 week low of $7.02 and a 52 week high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 272.31%. Sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.